BRAF V600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation
A subset of patients with chronic lymphocytic leukemia (CLL) and nearly all patients with classic hairy cell leukemia (HCL) harbor somatic BRAF activating mutations. However, the pathological role of activated BRAF in B-cell leukemia development and progression remains unclear. In addition, although...
Gespeichert in:
Veröffentlicht in: | Leukemia research 2015-09 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | |
container_title | Leukemia research |
container_volume | |
creator | Tsai, Yo-Ting Lozanski, Gerard Lehman, Amy Sass, Ellen J Hertlein, Erin Salunke, Santosh B Chen, Ching-Shih Grever, Michael R Byrd, John C Lucas, David M |
description | A subset of patients with chronic lymphocytic leukemia (CLL) and nearly all patients with classic hairy cell leukemia (HCL) harbor somatic BRAF activating mutations. However, the pathological role of activated BRAF in B-cell leukemia development and progression remains unclear. In addition, although HCL patients respond well to the BRAF
inhibitor vemurafenib, relapses are being observed, suggesting the development of drug resistance in patients with this mutation. To investigate the biological role of BRAF
in B-cell leukemia, we generated a CLL-like B-cell line, OSUCLL, with doxycycline-inducible BRAF
expression. Microarray and real-time PCR analysis showed that ABCB1 mRNA is upregulated in these cells, and P-glycoprotein (P-gp) expression as well as function were confirmed by immunoblot and rhodamine exclusion assays. Additionally, pharmacological inhibition of BRAF
and MEK alleviated the BRAF
-induced ABCB1/P-gp expression. ABCB1 reporter assays and gel shift assays demonstrated that AP-1 activity is crucial in this mechanism. This study, uncovers a pathological role for BRAF
in B-cell leukemia, and provides further evidence that combination strategies with inhibitors of BRAF
and MEK can be used to delay disease progression and occurrence of resistance. |
doi_str_mv | 10.1016/j.leukres.2015.08.017 |
format | Article |
fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_26350141</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>26350141</sourcerecordid><originalsourceid>FETCH-LOGICAL-p93t-7e6fed3009a7be5cdcba70cf7f644cfb6084c78b6539f36dc91237c290a5c7113</originalsourceid><addsrcrecordid>eNo1j9FKwzAYhYMgbk4fQckLtPv_pkmay3ZsKgwcMrwdaZKOzK4tTTvc21tQrw4c-L7DIeQJIUZAsTzFtRu_ehfiBJDHkMWA8obMMZMs4hnjM3IfwgkAuEJ1R2aJYBwwxTlxxUe-oZ8CYE19Y0fjAs2LVYHLXXSsr6bt-nZwvqHuu5sGgm8bqhtLbT8e6VT4MOjGuImlRWRcXQd68ZrmuwipNoO_6GFCHshtpevgHv9yQfab9X71Gm3fX95W-TbqFBsi6UTlLANQWpaOG2tKLcFUshJpaqpSQJYamZWCM1UxYY3ChEmTKNDcSES2IM-_2m4sz84eut6fdX89_N9lP3zQVt0</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>BRAF V600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation</title><source>Access via ScienceDirect (Elsevier)</source><creator>Tsai, Yo-Ting ; Lozanski, Gerard ; Lehman, Amy ; Sass, Ellen J ; Hertlein, Erin ; Salunke, Santosh B ; Chen, Ching-Shih ; Grever, Michael R ; Byrd, John C ; Lucas, David M</creator><creatorcontrib>Tsai, Yo-Ting ; Lozanski, Gerard ; Lehman, Amy ; Sass, Ellen J ; Hertlein, Erin ; Salunke, Santosh B ; Chen, Ching-Shih ; Grever, Michael R ; Byrd, John C ; Lucas, David M</creatorcontrib><description>A subset of patients with chronic lymphocytic leukemia (CLL) and nearly all patients with classic hairy cell leukemia (HCL) harbor somatic BRAF activating mutations. However, the pathological role of activated BRAF in B-cell leukemia development and progression remains unclear. In addition, although HCL patients respond well to the BRAF
inhibitor vemurafenib, relapses are being observed, suggesting the development of drug resistance in patients with this mutation. To investigate the biological role of BRAF
in B-cell leukemia, we generated a CLL-like B-cell line, OSUCLL, with doxycycline-inducible BRAF
expression. Microarray and real-time PCR analysis showed that ABCB1 mRNA is upregulated in these cells, and P-glycoprotein (P-gp) expression as well as function were confirmed by immunoblot and rhodamine exclusion assays. Additionally, pharmacological inhibition of BRAF
and MEK alleviated the BRAF
-induced ABCB1/P-gp expression. ABCB1 reporter assays and gel shift assays demonstrated that AP-1 activity is crucial in this mechanism. This study, uncovers a pathological role for BRAF
in B-cell leukemia, and provides further evidence that combination strategies with inhibitors of BRAF
and MEK can be used to delay disease progression and occurrence of resistance.</description><identifier>EISSN: 1873-5835</identifier><identifier>DOI: 10.1016/j.leukres.2015.08.017</identifier><identifier>PMID: 26350141</identifier><language>eng</language><publisher>England</publisher><ispartof>Leukemia research, 2015-09</ispartof><rights>Copyright © 2015 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27931,27932</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26350141$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tsai, Yo-Ting</creatorcontrib><creatorcontrib>Lozanski, Gerard</creatorcontrib><creatorcontrib>Lehman, Amy</creatorcontrib><creatorcontrib>Sass, Ellen J</creatorcontrib><creatorcontrib>Hertlein, Erin</creatorcontrib><creatorcontrib>Salunke, Santosh B</creatorcontrib><creatorcontrib>Chen, Ching-Shih</creatorcontrib><creatorcontrib>Grever, Michael R</creatorcontrib><creatorcontrib>Byrd, John C</creatorcontrib><creatorcontrib>Lucas, David M</creatorcontrib><title>BRAF V600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation</title><title>Leukemia research</title><addtitle>Leuk Res</addtitle><description>A subset of patients with chronic lymphocytic leukemia (CLL) and nearly all patients with classic hairy cell leukemia (HCL) harbor somatic BRAF activating mutations. However, the pathological role of activated BRAF in B-cell leukemia development and progression remains unclear. In addition, although HCL patients respond well to the BRAF
inhibitor vemurafenib, relapses are being observed, suggesting the development of drug resistance in patients with this mutation. To investigate the biological role of BRAF
in B-cell leukemia, we generated a CLL-like B-cell line, OSUCLL, with doxycycline-inducible BRAF
expression. Microarray and real-time PCR analysis showed that ABCB1 mRNA is upregulated in these cells, and P-glycoprotein (P-gp) expression as well as function were confirmed by immunoblot and rhodamine exclusion assays. Additionally, pharmacological inhibition of BRAF
and MEK alleviated the BRAF
-induced ABCB1/P-gp expression. ABCB1 reporter assays and gel shift assays demonstrated that AP-1 activity is crucial in this mechanism. This study, uncovers a pathological role for BRAF
in B-cell leukemia, and provides further evidence that combination strategies with inhibitors of BRAF
and MEK can be used to delay disease progression and occurrence of resistance.</description><issn>1873-5835</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNo1j9FKwzAYhYMgbk4fQckLtPv_pkmay3ZsKgwcMrwdaZKOzK4tTTvc21tQrw4c-L7DIeQJIUZAsTzFtRu_ehfiBJDHkMWA8obMMZMs4hnjM3IfwgkAuEJ1R2aJYBwwxTlxxUe-oZ8CYE19Y0fjAs2LVYHLXXSsr6bt-nZwvqHuu5sGgm8bqhtLbT8e6VT4MOjGuImlRWRcXQd68ZrmuwipNoO_6GFCHshtpevgHv9yQfab9X71Gm3fX95W-TbqFBsi6UTlLANQWpaOG2tKLcFUshJpaqpSQJYamZWCM1UxYY3ChEmTKNDcSES2IM-_2m4sz84eut6fdX89_N9lP3zQVt0</recordid><startdate>20150905</startdate><enddate>20150905</enddate><creator>Tsai, Yo-Ting</creator><creator>Lozanski, Gerard</creator><creator>Lehman, Amy</creator><creator>Sass, Ellen J</creator><creator>Hertlein, Erin</creator><creator>Salunke, Santosh B</creator><creator>Chen, Ching-Shih</creator><creator>Grever, Michael R</creator><creator>Byrd, John C</creator><creator>Lucas, David M</creator><scope>NPM</scope></search><sort><creationdate>20150905</creationdate><title>BRAF V600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation</title><author>Tsai, Yo-Ting ; Lozanski, Gerard ; Lehman, Amy ; Sass, Ellen J ; Hertlein, Erin ; Salunke, Santosh B ; Chen, Ching-Shih ; Grever, Michael R ; Byrd, John C ; Lucas, David M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p93t-7e6fed3009a7be5cdcba70cf7f644cfb6084c78b6539f36dc91237c290a5c7113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tsai, Yo-Ting</creatorcontrib><creatorcontrib>Lozanski, Gerard</creatorcontrib><creatorcontrib>Lehman, Amy</creatorcontrib><creatorcontrib>Sass, Ellen J</creatorcontrib><creatorcontrib>Hertlein, Erin</creatorcontrib><creatorcontrib>Salunke, Santosh B</creatorcontrib><creatorcontrib>Chen, Ching-Shih</creatorcontrib><creatorcontrib>Grever, Michael R</creatorcontrib><creatorcontrib>Byrd, John C</creatorcontrib><creatorcontrib>Lucas, David M</creatorcontrib><collection>PubMed</collection><jtitle>Leukemia research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tsai, Yo-Ting</au><au>Lozanski, Gerard</au><au>Lehman, Amy</au><au>Sass, Ellen J</au><au>Hertlein, Erin</au><au>Salunke, Santosh B</au><au>Chen, Ching-Shih</au><au>Grever, Michael R</au><au>Byrd, John C</au><au>Lucas, David M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>BRAF V600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation</atitle><jtitle>Leukemia research</jtitle><addtitle>Leuk Res</addtitle><date>2015-09-05</date><risdate>2015</risdate><eissn>1873-5835</eissn><abstract>A subset of patients with chronic lymphocytic leukemia (CLL) and nearly all patients with classic hairy cell leukemia (HCL) harbor somatic BRAF activating mutations. However, the pathological role of activated BRAF in B-cell leukemia development and progression remains unclear. In addition, although HCL patients respond well to the BRAF
inhibitor vemurafenib, relapses are being observed, suggesting the development of drug resistance in patients with this mutation. To investigate the biological role of BRAF
in B-cell leukemia, we generated a CLL-like B-cell line, OSUCLL, with doxycycline-inducible BRAF
expression. Microarray and real-time PCR analysis showed that ABCB1 mRNA is upregulated in these cells, and P-glycoprotein (P-gp) expression as well as function were confirmed by immunoblot and rhodamine exclusion assays. Additionally, pharmacological inhibition of BRAF
and MEK alleviated the BRAF
-induced ABCB1/P-gp expression. ABCB1 reporter assays and gel shift assays demonstrated that AP-1 activity is crucial in this mechanism. This study, uncovers a pathological role for BRAF
in B-cell leukemia, and provides further evidence that combination strategies with inhibitors of BRAF
and MEK can be used to delay disease progression and occurrence of resistance.</abstract><cop>England</cop><pmid>26350141</pmid><doi>10.1016/j.leukres.2015.08.017</doi></addata></record> |
fulltext | fulltext |
identifier | EISSN: 1873-5835 |
ispartof | Leukemia research, 2015-09 |
issn | 1873-5835 |
language | eng |
recordid | cdi_pubmed_primary_26350141 |
source | Access via ScienceDirect (Elsevier) |
title | BRAF V600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T11%3A25%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=BRAF%20V600E%20induces%20ABCB1/P-glycoprotein%20expression%20and%20drug%20resistance%20in%20B-cells%20via%20AP-1%20activation&rft.jtitle=Leukemia%20research&rft.au=Tsai,%20Yo-Ting&rft.date=2015-09-05&rft.eissn=1873-5835&rft_id=info:doi/10.1016/j.leukres.2015.08.017&rft_dat=%3Cpubmed%3E26350141%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/26350141&rfr_iscdi=true |